CapsoVision presents plans for CapsoCam Colon Gen 2 FDA submission in Q4 2026
CV•CapsoVision expects to submit CapsoCam Colon Gen 2 for FDA clearance in Q4 2026, targeting an initial $1 billion U.S. market. CapsoCam Plus generated $3.6 million in third-quarter 2026 revenue.
1. FDA submission plans
CapsoVision expects to submit CapsoCam Colon Gen 2 for FDA clearance in Q4 2026, targeting an initial $1 billion U.S. market.
2. Revenue and financing
CapsoCam Plus generated $3.6 million in third-quarter 2026 revenue. CapsoVision said its small-bowel AI module launched in the U.S. on November 2, after FDA clearance on September 25. The company completed an $18 million registered direct offering in September and established a $100 million ATM facility in August. No debt was outstanding as of September 30, 2026.
